FMP

FMP

Enter

NCNA - NuCana plc

photo-url-https://images.financialmodelingprep.com/symbol/NCNA.png

NuCana plc

NCNA

NASDAQ

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors and in a Phase 1b/2 clinical trial for patients with advanced colorectal cancer; and NUC-7738, a nucleoside analog that is in Phase 1/2 clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

1.19 USD

-0.22 (-18.49%)

Free Cash Flow

Year

2019

2020

2021

2022

2023

2024

2025

2026

2027

2028

Revenue

-

-

-

-

-

-

-

-

-

-

Revenue %

-

-

-

-

-

-

-

-

-

Operating Cash Flow

-29.84M

-27.06M

-29.82M

-28.99M

-33.1M

-

-

-

-

-

Operating Cash Flow %

100

100

100

100

100

100

100

100

100

Cap Ex

-1.58M

-2.04M

-1.33M

-648.46k

-598.38k

-

-

-

-

-

Cap Ex %

100

100

100

100

100

-

-

-

-

Free Cash Flow

-31.41M

-29.11M

-31.16M

-29.64M

-33.7M

-

-

-

-

-

Weighted Average Cost Of Capital

Price

1.19

Beta

Diluted Shares Outstanding

2.11M

Costof Debt

278.54

Tax Rate

After Tax Cost Of Debt

240.29

Risk Free Rate

Market Risk Premium

Cost Of Equity

Total Debt

495.73k

Total Equity

2.51M

Total Capital

3M

Debt Weighting

16.51

Equity Weighting

83.49

Wacc

46.61

Build Up Free Cash Flow

Year

2019

2020

2021

2022

2023

2024

2025

2026

2027

2028

Revenue

-

-

-

-

-

-

-

-

-

-

Operating Cash Flow

-29.84M

-27.06M

-29.82M

-28.99M

-33.1M

-

-

-

-

-

Cap Ex

-1.58M

-2.04M

-1.33M

-648.46k

-598.38k

-

-

-

-

-

Free Cash Flow

-31.41M

-29.11M

-31.16M

-29.64M

-33.7M

-

-

-

-

-

Wacc

46.61

46.61

46.61

46.61

46.61

Pv Lfcf

-

-

-

-

-

Sum Pv Lfcf

-

Terminal Value

Growth In Perpetuity Method

Long Term Growth Rate

Wacc

46.61

Free Cash Flow T1

0

Terminal Value

0

Present Terminal Value

0

Intrinsic Value

Enterprise Value

0

Net Debt

-21.07M

Equity Value

21.07M

Diluted Shares Outstanding

2.11M

Equity Value Per Share

10

Projected DCF

10 0.881%

DCF Levered

Download Excel

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep